Cargando…

Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma

Immune checkpoint inhibitors (ICIs) have considerably expanded the effective treatment options for malignant melanoma. ICIs revert tumor-associated immunosuppression and potentiate T-cell mediated tumor clearance. Immune-related neurologic adverse events (irNAEs) manifest in the central (CNS) or per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Teresa, Kebir, Sied, Livingstone, Elisabeth, Junker, Andreas, Zülow, Stefan, Lazaridis, Lazaros, Oster, Christoph, Chorti, Eleftheria, Pierscianek, Daniela, Pul, Refik, Keyvani, Kathy, Sure, Ulrich, Stuschke, Martin, Kleinschnitz, Christoph, Scheffler, Björn, Zimmer, Lisa, Glas, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081911/ https://www.ncbi.nlm.nih.gov/pubmed/33937037 http://dx.doi.org/10.3389/fonc.2021.637185

Ejemplares similares

Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report
por: Stoppek, Ann-Kathrin, et al.
Publicado: (2019)

Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023)

Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
por: Schmidt, Teresa, et al.
Publicado: (2023)

Telemedicine in Neuro-Oncology—An Evaluation of Remote Consultations during the COVID-19 Pandemic
por: Feldheim, Jonas, et al.
Publicado: (2023)

Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF‐phase I/II trial
por: Nour, Youness, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Preoperative and early postoperative seizures in patients with glioblastoma—two sides of the same coin?
por: Ahmadipour, Yahya, et al.
Publicado: (2020)

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2020)

Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis
por: Guberina, Nika, et al.
Publicado: (2023)

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
por: Glas, Martin, et al.
Publicado: (2019)

Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial
por: Guberina, N., et al.
Publicado: (2020)

Immunotherapies in chronic adhesive arachnoiditis - A case series and literature review
por: Hackert, Jana, et al.
Publicado: (2021)

How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis
por: Jabbarli, Ramazan, et al.
Publicado: (2021)

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
por: Schäfer, Niklas, et al.
Publicado: (2019)

MOG antibody–associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report
por: Escolà, Jordi Kühne, et al.
Publicado: (2022)

Brainstem Infarction in Immunodeficiency Identified as Adenosine Deaminase 2 Deficiency: Case Report
por: Oster, Christoph, et al.
Publicado: (2023)

Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS
por: Möhn, Nora, et al.
Publicado: (2020)

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
por: Schenk, Hannah, et al.
Publicado: (2022)

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases
por: Möhn, Nora, et al.
Publicado: (2020)

Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
por: Lu, I-Na, et al.
Publicado: (2021)

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma
por: Kebir, Sied, et al.
Publicado: (2016)

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
por: Scheffler, Armin, et al.
Publicado: (2021)

Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
por: Nsaka, Michael, et al.
Publicado: (2022)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
por: Scheffler, Armin, et al.
Publicado: (2020)

The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma
por: Gan, Chao, et al.
Publicado: (2020)

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
por: Kebir, Sied, et al.
Publicado: (2012)

Glyphosate-based herbicide: a risk factor for demyelinating conditions of the peripheral nervous system?
por: Szepanowski, Fabian, et al.
Publicado: (2019)

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients
por: Hattingen, Elke, et al.
Publicado: (2017)

BRMS1 in Gliomas—An Expression Analysis
por: Feldheim, Jonas, et al.
Publicado: (2023)

Severe and long-lasting alteration of albumin redox state by plasmapheresis
por: Boss, Kristina, et al.
Publicado: (2022)

Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice
por: Shi, Wenyin, et al.
Publicado: (2020)

Correction to: Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high‑grade glioma in clinical practice
por: Shi, Wenyin, et al.
Publicado: (2021)

Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells
por: Feldheim, Jonas, et al.
Publicado: (2022)

Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies
por: Feldheim, Jonas, et al.
Publicado: (2021)

A rare case of a completely thrombosed bilobed giant intracranial aneurysm of the anterior cerebral artery with spontaneous parent vessel thrombosis: case report
por: Chihi, Mehdi, et al.
Publicado: (2019)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Absence of Regulatory T Cells Causes Phenotypic and Functional Switch in Murine Peritoneal Macrophages
por: Skuljec, Jelena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dbt3rbvcenngnh6nfd17eglbjr